{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:06:45Z","timestamp":1787771205376,"version":"build-2784847793"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000646","name":"Japan Society for the Promotion of Science London","doi-asserted-by":"publisher","award":["21H02722"],"award-info":[{"award-number":["21H02722"]}],"id":[{"id":"10.13039\/501100000646","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000646","name":"Japan Society for the Promotion of Science London","doi-asserted-by":"publisher","award":["22H05057"],"award-info":[{"award-number":["22H05057"]}],"id":[{"id":"10.13039\/501100000646","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000646","name":"Japan Society for the Promotion of Science London","doi-asserted-by":"publisher","award":["24K02271"],"award-info":[{"award-number":["24K02271"]}],"id":[{"id":"10.13039\/501100000646","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004721","name":"The University of Tokyo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004721","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>B-cell activating factor belonging to the TNF family (BAFF), also known as B-lymphocyte stimulator (BLyS), plays a crucial role in B-cell development. It has multiple receptors, including BCMA, TACI, and BAFF-R, with diverse roles in different cell types. BAFF induces B-cell proliferation and immunoglobulin secretion, and acts as a survival factor for immature, naive, and activated B cells. Consequently, BAFF-deficient mice often show suppressed humoral responses, while BAFF-overexpressing mice show the higher number of mature B cells and may develop autoimmune-like manifestations and B-cell lymphoproliferative diseases. Elevated BAFF levels are also associated with various hematological malignancies, and its expression correlates with disease progression in some cases. Therefore, BAFF-targeted therapies, such as belimumab, atacicept, and tabalumab, are being explored in clinical trials for conditions like chronic lymphocytic leukemia (CLL) and multiple myeloma. Belimumab, an anti-BAFF monoclonal antibody, is being investigated in combination with rituximab\/venetoclax for CLL. Atacicept, a decoy receptor for BAFF and APRIL, showed tolerability in a phase 1b trial for CLL. Tabalumab, another monoclonal antibody targeting BAFF, did not demonstrate significant efficacy in a phase 2 study for relapsed\/refractory multiple myeloma. BAFF ligand-based CAR-T cells are designed to target BAFF receptors and show promise in preclinical studies, particularly for B-cell malignancies. The review emphasizes the importance of understanding the roles of BAFF and its receptors in the microenvironment of hematologic malignancies. Targeting BAFF and its receptors presents potential therapeutic avenues, and ongoing clinical trials provide valuable insights.<\/jats:p>","DOI":"10.1007\/s10147-024-02611-2","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T06:02:17Z","timestamp":1725256937000},"page":"1676-1683","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Current status of BAFF targeting immunotherapy in B-cell neoplasm"],"prefix":"10.1007","volume":"29","author":[{"given":"Nami","family":"Tagami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichiro","family":"Yuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8654-7888","authenticated-orcid":false,"given":"Yasuyuki","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,2]]},"reference":[{"key":"2611_CR1","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nri844","volume":"2","author":"F Mackay","year":"2002","unstructured":"Mackay F, Browning JL (2002) BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2:465\u2013475","journal-title":"Nat Rev Immunol"},{"key":"2611_CR2","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1126\/science.285.5425.260","volume":"285","author":"PA Moore","year":"1999","unstructured":"Moore PA, Belvedere O, Orr A et al (1999) BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 285:260\u2013263. https:\/\/doi.org\/10.1126\/science.285.5425.260","journal-title":"Science"},{"key":"2611_CR3","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1002\/jlb.65.5.680","volume":"65","author":"HB Shu","year":"1999","unstructured":"Shu HB, Hu WH, Johnson H (1999) TALL-1 is a novel member of the TNF family that is down-regulated by mitogens. J Leukoc Biol 65:680\u2013683. https:\/\/doi.org\/10.1002\/jlb.65.5.680","journal-title":"J Leukoc Biol"},{"key":"2611_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/35010115","author":"JA Gross","year":"2000","unstructured":"Gross JA, Johnston J, Mudri S et al (2000) TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature. https:\/\/doi.org\/10.1038\/35010115","journal-title":"Nature"},{"key":"2611_CR5","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.23.15978","author":"A Mukhopadhyay","year":"1999","unstructured":"Mukhopadhyay A, Ni J, Zhai Y et al (1999) Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-\u03baB, and c-jun NH2- terminal kinase. J Biol Chem. https:\/\/doi.org\/10.1074\/jbc.274.23.15978","journal-title":"J Biol Chem"},{"key":"2611_CR6","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1084\/jem.189.11.1747","volume":"189","author":"P Schneider","year":"1999","unstructured":"Schneider P, Mackay F, Steiner V et al (1999) BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 189:1747\u20131756. https:\/\/doi.org\/10.1084\/jem.189.11.1747","journal-title":"J Exp Med"},{"key":"2611_CR7","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.10.1453","author":"M Batten","year":"2000","unstructured":"Batten M, Groom J, Cachero TG et al (2000) BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med. https:\/\/doi.org\/10.1084\/jem.192.10.1453","journal-title":"J Exp Med"},{"key":"2611_CR8","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/nrrheum.2014.33","volume":"10","author":"FB Vincent","year":"2014","unstructured":"Vincent FB, Morand EF, Schneider P et al (2014) The BAFF\/APRIL system in SLE pathogenesis. Nat Rev Rheumatol 10:365\u2013373","journal-title":"Nat Rev Rheumatol"},{"key":"2611_CR9","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.smim.2006.04.005","volume":"18","author":"F Mackay","year":"2006","unstructured":"Mackay F, Leung H (2006) The role of the BAFF\/APRIL system on T cell function. Semin Immunol 18:284\u2013289","journal-title":"Semin Immunol"},{"key":"2611_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2013.04.003","author":"FB Vincent","year":"2013","unstructured":"Vincent FB, Saulep-Easton D, Figgett WA et al (2013) The BAFF\/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev. https:\/\/doi.org\/10.1016\/j.cytogfr.2013.04.003","journal-title":"Cytokine Growth Factor Rev"},{"key":"2611_CR11","doi-asserted-by":"publisher","DOI":"10.1084\/jem.188.6.1185","author":"M Hahne","year":"1998","unstructured":"Hahne M, Kataoka T, Schr\u00f6ter M et al (1998) APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med. https:\/\/doi.org\/10.1084\/jem.188.6.1185","journal-title":"J Exp Med"},{"key":"2611_CR12","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1146\/annurev.immunol.21.120601.141152","volume":"21","author":"F Mackay","year":"2003","unstructured":"Mackay F, Schneider P, Rennert P et al (2003) BAFF and APRIL: a tutorial on B cell survival. Annu Rev Immunol 21:231\u2013264","journal-title":"Annu Rev Immunol"},{"key":"2611_CR13","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.molimm.2004.06.041","volume":"42","author":"LG Ng","year":"2005","unstructured":"Ng LG, Mackay CR, Mackay F (2005) The BAFF\/APRIL system: life beyond B lymphocytes. Mol Immunol 42:763\u2013772","journal-title":"Mol Immunol"},{"key":"2611_CR14","doi-asserted-by":"publisher","DOI":"10.1093\/embo-reports\/kve198","author":"M L\u00f3pez-Fraga","year":"2001","unstructured":"L\u00f3pez-Fraga M, Fern\u00e1ndez R, Albar JP et al (2001) Biologically active APRIL is secreted following intracellular processing in the golgi apparatus by furin convertase. EMBO Rep. https:\/\/doi.org\/10.1093\/embo-reports\/kve198","journal-title":"EMBO Rep"},{"key":"2611_CR15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-1984","author":"J Moreaux","year":"2004","unstructured":"Moreaux J, Legouffe E, Jourdan E et al (2004) BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood. https:\/\/doi.org\/10.1182\/blood-2003-06-1984","journal-title":"Blood"},{"key":"2611_CR16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-02-0558","author":"AJ Novak","year":"2002","unstructured":"Novak AJ, Bram RJ, Kay NE et al (2002) Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood. https:\/\/doi.org\/10.1182\/blood-2002-02-0558","journal-title":"Blood"},{"key":"2611_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.10998.x","author":"H Ohmatsu","year":"2012","unstructured":"Ohmatsu H, Sugaya M, Miyagaki T et al (2012) BAFF levels are increased in lesional skin and sera in patients with cutaneous T-cell lymphoma. Br J Dermatol. https:\/\/doi.org\/10.1111\/j.1365-2133.2012.10998.x","journal-title":"Br J Dermatol"},{"key":"2611_CR18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0753","author":"P Neri","year":"2007","unstructured":"Neri P, Kumar S, Fulciniti MT et al (2007) Neutralizing B-cell-activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-0753","journal-title":"Clin Cancer Res"},{"key":"2611_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2014-000037","author":"M Schiff","year":"2015","unstructured":"Schiff M, Combe B, D\u00f6rner T et al (2015) Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: Results of a randomised, double-blind, placebo-controlled, phase 3 study. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2014-000037","journal-title":"RMD Open"},{"key":"2611_CR20","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-0190","author":"YT Tai","year":"2006","unstructured":"Tai YT, Li XF, Breitkreutz I et al (2006) Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-0190","journal-title":"Cancer Res"},{"key":"2611_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2008.01099.x","author":"SJ Kim","year":"2008","unstructured":"Kim SJ, Lee SJ, Choi IY et al (2008) Serum BAFF predicts prognosis better than APRIL in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP chemotherapy. Eur J Haematol. https:\/\/doi.org\/10.1111\/j.1600-0609.2008.01099.x","journal-title":"Eur J Haematol"},{"key":"2611_CR22","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20220214","author":"YR Miao","year":"2022","unstructured":"Miao YR, Thakkar K, Cenik C et al (2022) Developing high-affinity decoy receptors to treat multiple myeloma and diffuse large B cell lymphoma. J Exp Med. https:\/\/doi.org\/10.1084\/jem.20220214","journal-title":"J Exp Med"},{"key":"2611_CR23","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/j.1365-2567.2006.02377.x","volume":"118","author":"S Haiat","year":"2006","unstructured":"Haiat S, Billard C, Quiney C et al (2006) Role of BAFF and APRIL in human B-cell chronic lymphocytic leukaemia. Immunology 118:281\u2013292","journal-title":"Immunology"},{"key":"2611_CR24","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000000549","author":"B Sun","year":"2016","unstructured":"Sun B, Li L, Xu M et al (2016) Significance of BAFF\/APRIL expression and their receptors in pediatric patients with acute lymphoblastic leukemia. J Pediatr Hematol Oncol. https:\/\/doi.org\/10.1097\/MPH.0000000000000549","journal-title":"J Pediatr Hematol Oncol"},{"key":"2611_CR25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0008","author":"JO Claudio","year":"2002","unstructured":"Claudio JO, Masih-Khan E, Tang H et al (2002) A molecular compendium of genes expressed in multiple myeloma. Blood. https:\/\/doi.org\/10.1182\/blood-2002-01-0008","journal-title":"Blood"},{"key":"2611_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-472X(01)00774-3","author":"J Briones","year":"2002","unstructured":"Briones J, Timmerman JM, Hilbert DM et al (2002) BLyS and BLyS receptor expression in non-Hodgkin\u2019s lymphoma. Exp Hematol. https:\/\/doi.org\/10.1016\/S0301-472X(01)00774-3","journal-title":"Exp Hematol"},{"key":"2611_CR27","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.coph.2004.02.009","volume":"4","author":"F Mackay","year":"2004","unstructured":"Mackay F, Tangye SG (2004) The role of the BAFF\/APRIL system in B cell homeostasis and lymphoid cancers. Curr Opin Pharmacol 4:347\u2013354","journal-title":"Curr Opin Pharmacol"},{"key":"2611_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14483","author":"NS Raje","year":"2017","unstructured":"Raje NS, Moreau P, Terpos E et al (2017) Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma. Br J Haematol. https:\/\/doi.org\/10.1111\/bjh.14483","journal-title":"Br J Haematol"},{"key":"2611_CR29","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0201","author":"NS Raje","year":"2016","unstructured":"Raje NS, Faber EA, Richardson PG et al (2016) Phase 1 study of tabalumab, a human anti-B-cell activating factor antibody, and bortezomib in patients with relapsed\/refractory multiple myeloma. Clin Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0201","journal-title":"Clin Cancer Res"},{"key":"2611_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2178-x","author":"L Bolkun","year":"2015","unstructured":"Bolkun L, Lemancewicz D, Jablonska E et al (2015) The impact of TNF superfamily molecules on overall survival in acute myeloid leukaemia: correlation with biological and clinical features. Ann Hematol. https:\/\/doi.org\/10.1007\/s00277-014-2178-x","journal-title":"Ann Hematol"},{"key":"2611_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13000","author":"S Iida","year":"2016","unstructured":"Iida S, Ogiya D, Abe Y et al (2016) Dose-escalation study of tabalumab with bortezomib and dexamethasone in Japanese patients with multiple myeloma. Cancer Sci. https:\/\/doi.org\/10.1111\/cas.13000","journal-title":"Cancer Sci"},{"key":"2611_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2490-0","author":"Y Wang","year":"2015","unstructured":"Wang Y, Li YJ, Jiang WQ et al (2015) Expression of BAFF-R, but not BAFF, is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP. Ann Hematol. https:\/\/doi.org\/10.1007\/s00277-015-2490-0","journal-title":"Ann Hematol"},{"key":"2611_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0050936","author":"YJ Li","year":"2012","unstructured":"Li YJ, Jiang WQ, Rao HL et al (2012) Expression of BAFF and BAFF-R in follicular lymphoma: correlation with clinicopathologic characteristics and survival outcomes. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0050936","journal-title":"PLoS ONE"},{"key":"2611_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2173-2","author":"YJ Li","year":"2015","unstructured":"Li YJ, Li ZM, Xia ZJ et al (2015) High APRIL but not BAFF serum levels are associated with poor outcome in patients with follicular lymphoma. Ann Hematol. https:\/\/doi.org\/10.1007\/s00277-014-2173-2","journal-title":"Ann Hematol"},{"key":"2611_CR35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2010.01482.x","author":"S Molica","year":"2010","unstructured":"Molica S, Digiesi G, Battaglia C et al (2010) Baff serum level predicts time to first treatment in early chronic lymphocytic leukemia. Eur J Haematol. https:\/\/doi.org\/10.1111\/j.1600-0609.2010.01482.x","journal-title":"Eur J Haematol"},{"key":"2611_CR36","doi-asserted-by":"publisher","DOI":"10.7150\/jca.15966","author":"L Bolkun","year":"2016","unstructured":"Bolkun L, Grubczak K, Schneider G et al (2016) Involvement of BAFF and APRIL in resistance to apoptosis of acute myeloid leukemia. J Cancer. https:\/\/doi.org\/10.7150\/jca.15966","journal-title":"J Cancer"},{"key":"2611_CR37","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1126\/science.1061964","volume":"293","author":"B Schiemann","year":"2001","unstructured":"Schiemann B, Gommerman JLL, Vora K et al (2001) An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 293:2111\u20132114. https:\/\/doi.org\/10.1126\/science.1061964","journal-title":"Science"},{"key":"2611_CR38","doi-asserted-by":"publisher","DOI":"10.1111\/imcb.12585","author":"PS Quah","year":"2022","unstructured":"Quah PS, Sutton V, Whitlock E et al (2022) The effects of B-cell\u2013activating factor on the population size, maturation and function of murine natural killer cells. Immunol Cell Biol. https:\/\/doi.org\/10.1111\/imcb.12585","journal-title":"Immunol Cell Biol"},{"key":"2611_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(01)00183-2","author":"JA Gross","year":"2001","unstructured":"Gross JA, Dillon SR, Mudri S et al (2001) TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease: Impaired B cell maturation in mice lacking BLyS. Immunity. https:\/\/doi.org\/10.1016\/S1074-7613(01)00183-2","journal-title":"Immunity"},{"key":"2611_CR40","doi-asserted-by":"publisher","DOI":"10.1084\/jem.190.11.1697","author":"F Mackay","year":"1999","unstructured":"Mackay F, Woodcock SA, Lawton P et al (1999) Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med. https:\/\/doi.org\/10.1084\/jem.190.11.1697","journal-title":"J Exp Med"},{"key":"2611_CR41","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/nri2572","volume":"9","author":"F MacKay","year":"2009","unstructured":"MacKay F, Schneider P (2009) Cracking the BAFF code. Nat Rev Immunol 9:491\u2013502","journal-title":"Nat Rev Immunol"},{"key":"2611_CR42","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13602","author":"G Nocturne","year":"2021","unstructured":"Nocturne G, Ly B, Paoletti A et al (2021) Long-term exposure to monoclonal anti-TNF is associated with an increased risk of lymphoma in BAFF-transgenic mice. Clin Exp Immunol. https:\/\/doi.org\/10.1111\/cei.13602","journal-title":"Clin Exp Immunol"},{"key":"2611_CR43","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.2.812","author":"M Batten","year":"2004","unstructured":"Batten M, Fletcher C, Ng LG et al (2004) TNF deficiency fails to protect BAFF transgenic mice against autoimmunity and reveals a predisposition to B cell lymphoma. J Immunol. https:\/\/doi.org\/10.4049\/jimmunol.172.2.812","journal-title":"J Immunol"},{"key":"2611_CR44","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017010090","author":"J Lang","year":"2017","unstructured":"Lang J, Zhang B, Kelly M et al (2017) Replacing mouse BAFF with human BAFF does not improve B-cell maturation in hematopoietic humanized mice. Blood Adv. https:\/\/doi.org\/10.1182\/bloodadvances.2017010090","journal-title":"Blood Adv"},{"key":"2611_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-9822(01)00481-X","author":"M Yan","year":"2001","unstructured":"Yan M, Brady JR, Chan B et al (2001) Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. Curr Biol. https:\/\/doi.org\/10.1016\/S0960-9822(01)00481-X","journal-title":"Curr Biol"},{"key":"2611_CR46","doi-asserted-by":"publisher","DOI":"10.1126\/science.1061965","author":"JS Thompson","year":"1979","unstructured":"Thompson JS, Bixler SA, Qian F et al (1979) (2001) BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science. https:\/\/doi.org\/10.1126\/science.1061965","journal-title":"Science"},{"key":"2611_CR47","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.2.807","author":"LG Ng","year":"2004","unstructured":"Ng LG, Sutherland APR, Newton R et al (2004) B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol. https:\/\/doi.org\/10.4049\/jimmunol.173.2.807","journal-title":"J Immunol"},{"key":"2611_CR48","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2008.03203.x","author":"K Wada","year":"2009","unstructured":"Wada K, Maeda K, Tajima K et al (2009) Expression of BAFF-R and TACI in reactive lymphoid tissues and B-cell lymphomas. Histopathology. https:\/\/doi.org\/10.1111\/j.1365-2559.2008.03203.x","journal-title":"Histopathology"},{"key":"2611_CR49","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-016-5182-z","author":"M Jasek","year":"2016","unstructured":"Jasek M, Bojarska-Junak A, Wagner M et al (2016) Association of variants in BAFF (rs9514828 and rs1041569) and BAFF-R (rs61756766) genes with the risk of chronic lymphocytic leukemia. Tumor Biology. https:\/\/doi.org\/10.1007\/s13277-016-5182-z","journal-title":"Tumor Biology"},{"key":"2611_CR50","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2043","author":"AJ Novak","year":"2004","unstructured":"Novak AJ, Darce JR, Arendt BK et al (2004) Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood. https:\/\/doi.org\/10.1182\/blood-2003-06-2043","journal-title":"Blood"},{"key":"2611_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2008.04.006","author":"F Mackay","year":"2008","unstructured":"Mackay F, Schneider P (2008) TACI, an enigmatic BAFF\/APRIL receptor, with new unappreciated biochemical and biological properties. Cytokine Growth Factor Rev. https:\/\/doi.org\/10.1016\/j.cytogfr.2008.04.006","journal-title":"Cytokine Growth Factor Rev"},{"key":"2611_CR52","doi-asserted-by":"publisher","DOI":"10.1126\/science.278.5335.138","author":"GU Von B\u00fclow","year":"1979","unstructured":"Von B\u00fclow GU (1979) Bram RJ (1997) NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily. Science. https:\/\/doi.org\/10.1126\/science.278.5335.138","journal-title":"Science"},{"key":"2611_CR53","doi-asserted-by":"publisher","DOI":"10.1172\/JCI74428","author":"S Tsuji","year":"2014","unstructured":"Tsuji S, Stein L, Kamada N et al (2014) TACI deficiency enhances antibody avidity and clearance of an intestinal pathogen. J Clin Investig. https:\/\/doi.org\/10.1172\/JCI74428","journal-title":"J Clin Investig"},{"key":"2611_CR54","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-353961","author":"S Tsuji","year":"2011","unstructured":"Tsuji S, Cortes\u00e3o C, Bram RJ et al (2011) TACI deficiency impairs sustained Blimp-1 expression in B cells decreasing long-lived plasma cells in the bone marrow. Blood. https:\/\/doi.org\/10.1182\/blood-2011-05-353961","journal-title":"Blood"},{"key":"2611_CR55","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1200386109","author":"X Ou","year":"2012","unstructured":"Ou X, Xu S, Lam KP (2012) Deficiency in TNFRSF13B (TACI) expands T-follicular helper and germinal center B cells via increased ICOS-ligand expression but impairs plasma cell survival. Proc Natl Acad Sci U S A. https:\/\/doi.org\/10.1073\/pnas.1200386109","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2611_CR56","first-page":"1","volume":"2015","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Li J, Zhang YM et al (2015) Effect of TACI signaling on humoral immunity and autoimmune diseases. J Immunol Res 2015:1\u201312","journal-title":"J Immunol Res"},{"key":"2611_CR57","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-2221","author":"A Enjuanes","year":"2008","unstructured":"Enjuanes A, Benavente Y, Bosch F et al (2008) Genetic variants in apoptosis and immunoregulation-related genes are associated with risk of chronic lymphocytic leukemia. Cancer Res. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-2221","journal-title":"Cancer Res"},{"key":"2611_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.196","author":"SK Kumar","year":"2012","unstructured":"Kumar SK, Lee JH, Lahuerta JJ et al (2012) Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. https:\/\/doi.org\/10.1038\/leu.2011.196","journal-title":"Leukemia"},{"key":"2611_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.174","author":"D Saulep-Easton","year":"2016","unstructured":"Saulep-Easton D, Vincent FB, Quah PS et al (2016) The BAFF receptor TACI controls IL-10 production by regulatory B cells and CLL B cells. Leukemia. https:\/\/doi.org\/10.1038\/leu.2015.174","journal-title":"Leukemia"},{"key":"2611_CR60","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.1.129","author":"JS Thompson","year":"2000","unstructured":"Thompson JS, Schneider P, Kalled SL et al (2000) BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population. J Exp Med. https:\/\/doi.org\/10.1084\/jem.192.1.129","journal-title":"J Exp Med"},{"key":"2611_CR61","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/10.11.1693","author":"C Madry","year":"1998","unstructured":"Madry C, Laabi Y, Callebaut I et al (1998) The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily. Int Immunol. https:\/\/doi.org\/10.1093\/intimm\/10.11.1693","journal-title":"Int Immunol"},{"key":"2611_CR62","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1080\/10428194.2022.2133540","volume":"64","author":"M Alomari","year":"2023","unstructured":"Alomari M, Kunacheewa C, Manasanch EE (2023) The role of soluble B cell maturation antigen as a biomarker in multiple myeloma. Leuk Lymphoma 64:261\u2013272","journal-title":"Leuk Lymphoma"},{"key":"2611_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8333","author":"SA Laurent","year":"2015","unstructured":"Laurent SA, Hoffmann FS, Kuhn PH et al (2015) \u03b3-secretase directly sheds the survival receptor BCMA from plasma cells. Nat Commun. https:\/\/doi.org\/10.1038\/ncomms8333","journal-title":"Nat Commun"},{"key":"2611_CR64","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09241.x","author":"E Sanchez","year":"2012","unstructured":"Sanchez E, Li M, Kitto A et al (2012) Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br J Haematol. https:\/\/doi.org\/10.1111\/j.1365-2141.2012.09241.x","journal-title":"Br J Haematol"},{"key":"2611_CR65","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.150896","author":"M Ghermezi","year":"2017","unstructured":"Ghermezi M, Li M, Vardanyan S et al (2017) Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients. Haematologica. https:\/\/doi.org\/10.3324\/haematol.2016.150896","journal-title":"Haematologica"},{"key":"2611_CR66","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2224","author":"E Sanchez","year":"2016","unstructured":"Sanchez E, Gillespie A, Tang G et al (2016) Soluble B-cell maturation antigen mediates tumor-induced immune deficiency in multiple myeloma. Clin Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2224","journal-title":"Clin Cancer Res"},{"key":"2611_CR67","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-019-00666-0","author":"KA Udd","year":"2019","unstructured":"Udd KA, Bujarski S, Wirtschafter E et al (2019) Plasma B-cell maturation antigen levels are elevated and correlate with disease activity in patients with chronic lymphocytic leukemia. Target Oncol. https:\/\/doi.org\/10.1007\/s11523-019-00666-0","journal-title":"Target Oncol"},{"key":"2611_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01245-5","author":"MC Da Vi\u00e0","year":"2021","unstructured":"Da Vi\u00e0 MC, Dietrich O, Truger M et al (2021) Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. Nat Med. https:\/\/doi.org\/10.1038\/s41591-021-01245-5","journal-title":"Nat Med"},{"key":"2611_CR69","doi-asserted-by":"publisher","DOI":"10.1002\/art.11299","author":"KP Baker","year":"2003","unstructured":"Baker KP, Edwards BM, Main SH et al (2003) Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. https:\/\/doi.org\/10.1002\/art.11299","journal-title":"Arthritis Rheum"},{"key":"2611_CR70","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1002\/iub.1046","volume":"64","author":"K Fairfax","year":"2012","unstructured":"Fairfax K, MacKay IR, MacKay F (2012) BAFF\/BLyS inhibitors: a new prospect for treatment of systemic lupus erythematosus. IUBMB Life 64:595\u2013602","journal-title":"IUBMB Life"},{"key":"2611_CR71","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2001180","author":"R Furie","year":"2020","unstructured":"Furie R, Rovin BH, Houssiau F et al (2020) Two-year, randomized, controlled trial of belimumab in lupus nephritis. New England J Med. https:\/\/doi.org\/10.1056\/nejmoa2001180","journal-title":"New England J Med"},{"key":"2611_CR72","unstructured":"Belimumab in Patients With Chronic Lymphocytic Leukemia (BeliVeR)"},{"key":"2611_CR73","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12982","author":"M Pitsiu","year":"2023","unstructured":"Pitsiu M, Yalkinoglu \u00d6, Farrell C et al (2023) Population pharmacokinetics of atacicept in systemic lupus erythematosus: an analysis of three clinical trials. CPT Pharmacometrics Syst Pharmacol. https:\/\/doi.org\/10.1002\/psp4.12982","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2611_CR74","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00433","author":"C Kaegi","year":"2020","unstructured":"Kaegi C, Steiner UC, Wuest B et al (2020) Systematic review of safety and efficacy of atacicept in treating immune-mediated disorders. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2020.00433","journal-title":"Front Immunol"},{"key":"2611_CR75","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/leu.2011.286","volume":"26","author":"DM Kofler","year":"2012","unstructured":"Kofler DM, Gawlik BB, Elter T et al (2012) Phase 1b trial of atacicept, a recombinant protein binding BLyS and APRIL, in patients with chronic lymphocytic leukemia. Leukemia 26:841\u2013844","journal-title":"Leukemia"},{"key":"2611_CR76","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207653","author":"DA Isenberg","year":"2016","unstructured":"Isenberg DA, Petri M, Kalunian K et al (2016) Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: Results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207653","journal-title":"Ann Rheum Dis"},{"key":"2611_CR77","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.3390\/cancers15061791","volume":"15","author":"MA Ullah","year":"2023","unstructured":"Ullah MA, Mackay F (2023) The BAFF-APRIL system in cancer. Cancers (Basel) 15:1791","journal-title":"Cancers (Basel)"},{"key":"2611_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27853-w","author":"DP Wong","year":"2022","unstructured":"Wong DP, Roy NK, Zhang K et al (2022) A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers. Nat Commun. https:\/\/doi.org\/10.1038\/s41467-021-27853-w","journal-title":"Nat Commun"},{"key":"2611_CR79","unstructured":"Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma"},{"key":"2611_CR80","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.3390\/ijms24032336","volume":"24","author":"G Kumar","year":"2023","unstructured":"Kumar G, Axtell RC (2023) Dual role of B cells in multiple sclerosis. Int J Mol Sci 24:2336","journal-title":"Int J Mol Sci"},{"key":"2611_CR81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12013-008-9036-1","volume":"53","author":"JF Treml","year":"2009","unstructured":"Treml JF, Hao Y, Stadanlick JE et al (2009) The BLyS family: Toward a molecular understanding of B cell homeostasis. Cell Biochem Biophys 53:1\u201316","journal-title":"Cell Biochem Biophys"},{"key":"2611_CR82","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12967-020-02289-w","volume":"18","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Zhang Y, Han J et al (2020) Transitional B cells involved in autoimmunity and their impact on neuroimmunological diseases. J Transl Med 18:131","journal-title":"J Transl Med"},{"key":"2611_CR83","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.3389\/fimmu.2018.02285","volume":"9","author":"CR Smulski","year":"2018","unstructured":"Smulski CR, Eibel H (2018) BAFF and BAFF-receptor in B cell selection and survival. Front Immunol 9:2285","journal-title":"Front Immunol"},{"key":"2611_CR84","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1128\/CMR.00046-17\/ASSET\/03F3F2C6-E71A-4164-8643-1048821A92E7\/ASSETS\/GRAPHIC\/ZCM0041726020004.JPEG","volume":"30","author":"J Sakai","year":"2017","unstructured":"Sakai J, Akkoyunlu M (2017) The role of BAFF system molecules in host response to pathogens. Clin Microbiol Rev 30:991\u20131014. https:\/\/doi.org\/10.1128\/CMR.00046-17\/ASSET\/03F3F2C6-E71A-4164-8643-1048821A92E7\/ASSETS\/GRAPHIC\/ZCM0041726020004.JPEG","journal-title":"Clin Microbiol Rev"},{"key":"2611_CR85","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.8.5128-c","author":"B He","year":"2004","unstructured":"He B, Chadburn A, Jou E et al (2004) Lymphoma B cells evade apoptosis through the TNF family members BAFF\/BLyS and APRIL. J Immunol. https:\/\/doi.org\/10.4049\/jimmunol.172.8.5128-c","journal-title":"J Immunol"},{"key":"2611_CR86","doi-asserted-by":"publisher","first-page":"2000047","DOI":"10.1002\/anbr.202000047","volume":"1","author":"EH Powsner","year":"2021","unstructured":"Powsner EH, Harris JC, Day ES (2021) Biomimetic nanoparticles for the treatment of hematologic malignancies. Adv Nanobiomed Res 1:2000047","journal-title":"Adv Nanobiomed Res"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02611-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-024-02611-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02611-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T21:02:35Z","timestamp":1729890155000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-024-02611-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,2]]},"references-count":86,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["2611"],"URL":"https:\/\/doi.org\/10.1007\/s10147-024-02611-2","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,2]]},"assertion":[{"value":"17 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NT is an employee of Sanofi K.K., but this work was performed as a part of NT\u2019s graduate study at the University of Tokyo, independently from the company. JY received fundings from AbbVie, Daiichi Sankyo, Chugai, Genmab, Novartis, Amgen, Takeda, BMS, Incyte, Janssen, Sumitomo, MSD, and Mitsubishi Tanabe. YG has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}